| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PFE | Common Stock | Options Exercise | $408,788 | +14,952 | +22% | $27.34 | 81,518 | 23 Feb 2022 | Direct | F1 |
| transaction | PFE | Common Stock | Tax liability | $137,188 | -2,927 | -3.6% | $46.87 | 78,591 | 23 Feb 2022 | Direct | F2 |
| transaction | PFE | Common Stock | Tax liability | $379,523 | -7,401 | -9.4% | $51.28 | 71,190 | 23 Feb 2022 | Direct | F3, F4 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PFE | Stock Appreciation Rights | Options Exercise | $0 | -14,952 | -100% | $0.000000* | 0 | 23 Feb 2022 | Common Stock | 14,952 | $27.34 | Direct | F5 |
| transaction | PFE | Stock Appreciation Rights | Award | $0 | +34,234 | $0.000000 | 34,234 | 24 Feb 2022 | Common Stock | 34,234 | $45.96 | Direct | F5 | |
| transaction | PFE | Stock Appreciation Rights | Award | $0 | +30,109 | $0.000000 | 30,109 | 24 Feb 2022 | Common Stock | 30,109 | $45.96 | Direct | F6 |
| Id | Content |
|---|---|
| F1 | The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). |
| F2 | The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. |
| F3 | The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). |
| F4 | Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |
| F5 | The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. |
| F6 | The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. |